Two Agents Show Promise for Hyperkalemia

Share this content:
Two Agents Show Promise for Hyperkalemia
Two Agents Show Promise for Hyperkalemia

MONDAY, Nov. 24, 2014 (HealthDay News) -- For patients with hyperkalemia, sodium zirconium cyclosilicate (ZS-9) and patiromer show promise for reducing potassium levels, according to two studies published online Nov. 21 in the New England Journal of Medicine.

David K. Packham, M.B., B.S., M.D., from the Royal Melbourne Hospital in Australia, and colleagues randomized 753 patients with hyperkalemia to receive ZS-9 or placebo for 48 hours. The researchers found that the mean reductions for patients receiving 2.5 g, 5 g, and 10 g ZS-9 were 0.5, 0.5, and 0.7 mmol/L, respectively (P < 0.001 for all comparisons with placebo). Serum potassium levels were maintained at 4.7 and 4.5 mmol/L during days three to 15 for those who received 5 g and 10 g of ZS-9, respectively, compared with a level of more than 5.0 mmol/L for the placebo group (all comparisons, P < 0.01).

Matthew R. Weir, M.D., from the University of Maryland School of Medicine in Baltimore, and colleagues assessed the safety and efficacy of patiromer among patients with chronic kidney disease. The researchers found that the mean change in the serum potassium level was −1.01 ± 0.03 mmol/L (P < 0.001) among 237 patients receiving patiromer. Seventy-six percent of patients had reached the target potassium level at week four. In a randomized withdrawal phase, hyperkalemia recurrence occurred in 60 percent of patients in the placebo group versus 15 percent in the patiromer group (P < 0.001).

"Both agents appear to offer some promise for the treatment of hyperkalemia in patients with chronic kidney and cardiac disease," write the authors of an accompanying editorial.

The Packham study was funded by ZS Pharma, the manufacturer of ZS-9; the Weir study was funded by Relypsa, the manufacturer of patiromer.

Abstract - Packham
Full Text
Abstract - Weir
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical Trial

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical ...

Clovers trial seeks to determine which IV fluids, vasopressors combo works best to curb sepsis

Education Can Up Emotional Intelligence in Residents

Education Can Up Emotional Intelligence in Residents

Increase in total EI median scores, stress management composite score after intervention

Cancer-Related Gene Variations Frequently Reclassified

Cancer-Related Gene Variations Frequently Reclassified

24.9 percent of variants of uncertain significance were reclassified at a single commercial laboratory

is free, fast, and customized just for you!




Already a member?

Sign In Now »